Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.

Leukemia & lymphoma - 1 Aug 2026

Agarwal Gaurav, Tonk Rajiv Kumar, Sangwan Kavita

Abstract excerpt

Understanding the clinical significance of genetic aberrations in acute myeloid leukemia (AML) has led to the development of several specific treatment drugs that have improved clinical outcomes. Recently, several clinical trials have investigated new therapeutic drugs in this context, either alone or in combination with intensive chemotherapy or low-intensity treatments. Among these, menin inhibitors may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Gene Rearrangement
Share to Histone-Lysine N-Methyltransferase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Molecular Targeted Therapy

Share to Myeloid-Lymphoid Leukemia Protein

Share to Nucleophosmin

Share to Proto-Oncogene Proteins

Source

Identifiers

PMID: 42200794
DOI: 10.1080/10428194.2026.2674818

Genes

NPM1
KMT2A
BMF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.PMID 42200794Read ↗

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read ↗

Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacySemantic proximity Read ↗

Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.Semantic proximity Read ↗

Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 MutationSemantic proximity Read ↗

Revumenib for patients with acute leukemia: a new tool for differentiation therapySemantic proximity Read ↗

Combination Strategies with Menin Inhibitors for Acute LeukemiaSemantic proximity Read ↗

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.Semantic proximity Read ↗

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 StudySemantic proximity Read ↗

The promise of menin inhibitors: from approval to triplet regimens.Semantic proximity Read ↗

Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?Semantic proximity Read ↗

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.